Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEC | P42680 | 1/20 | 0.56 |
| ▸ | TXK | P42681 | 1/20 | 0.56 |
| ▸ | BTK | Q06187 | 10/20 | 0.51 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 7/20 | 0.45 |
| ▸ | LCK | P06239 | 2/20 | 0.44 |
| ▸ | LYN | P07948 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14651434 | 1.00 | TEC (0.56) | TECTXKBTKTNK2IGF1R | |
| SCHEMBL20411767 | 0.97 | TEC (0.54) | TECTXKBTKTNK2IGF1R | |
| SCHEMBL20411769 | 0.97 | TEC (0.54) | TECTXKBTKTNK2IGF1R | |
| Sulfuric Acid SCHEMBL20550717 | 0.97 | TEC (0.54) | TECTXKBTKTNK2IGF1R | |
| SCHEMBL14637977 | 0.96 | TEC (0.53) | TECTXKBTKTNK2IGF1R | |
| SCHEMBL28351756 | 0.90 | TEC (0.48) | TECTXKBTKTNK2IGF1R | |
| SCHEMBL28351758 | 0.90 | TEC (0.48) | TECTXKBTKTNK2IGF1R | |
| SCHEMBL14651433 | 0.89 | TEC (0.47) | TECTXKBTK | |
| SCHEMBL21783734 | 0.89 | TEC (0.47) | TECTXKBTK | |
| SCHEMBL14654694 | 0.89 | TEC (0.49) | TECTXKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001885-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | MERCK SHARP & DOHME (NL) | 2026-01-01 | — | — | US | disclosed |
| CN-108658990-B | Novel imidazo [1,5-a ] pyrazine Bruton kinase inhibitors | 南京科技职业学院 | 2021-03-23 | — | — | CN | disclosed |
| WO-2020043787-A1 | PROCESSES FOR THE PREPARATION OF 4-{8-AMINO-3-[(2S)-1-(BUT-2-YNOYL)-PYRROLIDIN-2-YL]IMIDAZO[1,5-A]-PYRAZIN-1-YL}N-(PYRIDIN-2-YL)-BENZAMIDE | ACERTA PHARMA B.V. (NL) | 2020-03-05 | — | — | WO | disclosed |
| EP-2734522-A1 | 4 - IMIDAZOPYRIDAZIN- 1 -YL-BENZAMIDES AND 4 - IMIDAZOTRIAZIN- 1 - YL - BENZAMIDES AS BTK- INHIBITORS | Merck Sharp & Dohme B.V. (NL) | 2014-05-28 | — | — | EP | disclosed |
| WO-2013010868-A1 | 4 - IMIDAZOPYRIDAZIN- 1 -YL-BENZAMIDES AND 4 - IMIDAZOTRIAZIN- 1 - YL - BENZAMIDES AS BTK- INHIBITORS | MSD OSS B.V. (NL) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013010868-A1 | 4 - IMIDAZOPYRIDAZIN- 1 -YL-BENZAMIDES AND 4 - IMIDAZOTRIAZIN- 1 - YL - BENZAMIDES AS BTK- INHIBITORS | MSD OSS B.V. (NL) | 2013-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001885-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | BTK, ABL1, FLT3 | TEC 15/4885TXK 63/4885BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.